Zwijndrecht

Researchers are conducting a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b trial to evaluate the effectiveness, safety, and tolerability of IMVT-1402 in adults with Graves' disease who remain hyperthyroid despite antithyroid drug treatment. The study focuses on participants aged 18 to 75 years who have this diagnosis and are still experiencing hyperthyroidism. Participants will receive either IMVT-1402 or a placebo for 26 weeks. The study includes two dosing regimens of IMVT-1402: Dose 1 administered for 26 weeks and Dose 2 also administered for 26 weeks. The placebo group will receive treatment for the same duration. The treatments are given as drugs, and the study is designed to keep both participants and researchers unaware of which treatment is assigned. During the study, researchers will monitor participants to see how many achieve normal thyroid function (euthyroid) and remain off antithyroid drugs by Week 26. Participants will be assessed regularly to evaluate safety, tolerability, and treatment effects. The involvement includes following the assigned treatment and attending scheduled visits for evaluations. The total participation time corresponds with the 26-week treatment period.

Researchers are evaluating the effect of muvalaplin on reducing cardiovascular risk in adults with elevated lipoprotein(a) levels who either have atherosclerotic cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high Lp(a) levels and prior or potential cardiovascular events. The study aims to assess the time to the first major adverse cardiovascular event over about 5.25 years. Participants will be randomly assigned to receive either muvalaplin or a placebo, both administered orally. The study includes individuals with Lp(a) levels of at least 175 nanomoles per liter who have had a prior cardiovascular event within 10 years or are at risk for a first event due to conditions such as coronary artery disease, carotid stenosis, peripheral artery disease, high coronary artery calcium score, reduced kidney function with diabetes, or other high-risk factors. The treatment period lasts through the study duration, with close monitoring. During the study, participants will be regularly evaluated to track the occurrence of major adverse cardiovascular events, including heart attacks and strokes. Safety assessments will monitor blood pressure, kidney function, and heart failure status among other health indicators. The primary outcome measures the time to the first major cardiovascular event from baseline up to the end of the study, which spans approximately 5.25 years.

Chemotherapy induced peripheral neuropathy (CIPN) is a common and serious condition affecting up to 40% of patients who undergo chemotherapy, causing painful neuropathic symptoms. This research investigates the effectiveness of closed-loop spinal cord stimulation (CL-SCS) therapy, which is designed to treat painful CIPN by automatically adjusting stimulation levels in real time based on nerve responses. The study aims to assess pain reduction and improvement in quality of life for patients receiving this therapy. The closed-loop SCS system works by stimulating the dorsal column of the spinal cord and measuring nerve response to tailor the stimulation for each pulse delivered. Patients selected for this study will have planned implantation of the Evoke SCS System. The therapy is evaluated over several time points to understand its impact on pain intensity and overall symptom management in patients who have had CIPN for at least 3 months and are post-chemotherapy remission. Participants will be monitored and evaluated at baseline and at 1, 3, 6, and 12 months after the SCS implantation to measure changes in overall pain intensity. Assessments include patient-reported pain scores and quality of life measures, with careful follow-up to track treatment effectiveness and safety. The study requires patients to have persistent pain despite other treatments and includes ongoing data collection to provide comprehensive insights into the therapy's impact over a year.